



REVIEW

Filaments and phenotypes: cellular roles and orphan effects associated with mutations in cytoplasmic intermediate filament proteins [version 1; peer review: 2 approved]

Michael W. Klymkowsky

Molecular, Cellular & Developmental Biology, University of Colorado, Boulder, Boulder, CO, 80303, USA

v1 **First published:** 30 Sep 2019, 8(F1000 Faculty Rev):1703 (<https://doi.org/10.12688/f1000research.19950.1>)
Latest published: 30 Sep 2019, 8(F1000 Faculty Rev):1703 (<https://doi.org/10.12688/f1000research.19950.1>)

Abstract

Cytoplasmic intermediate filaments (IFs) surround the nucleus and are often anchored at membrane sites to form effectively transcellular networks. Mutations in IF proteins (IFPs) have revealed mechanical roles in epidermis, muscle, liver, and neurons. At the same time, there have been phenotypic surprises, illustrated by the ability to generate viable and fertile mice null for a number of IFp-encoding genes, including vimentin. Yet in humans, the vimentin (*VIM*) gene displays a high probability of intolerance to loss-of-function mutations, indicating an essential role. A number of subtle and not so subtle IF-associated phenotypes have been identified, often linked to mechanical or metabolic stresses, some of which have been found to be ameliorated by the over-expression of molecular chaperones, suggesting that such phenotypes arise from what might be termed “orphan” effects as opposed to the absence of the IF network *per se*, an idea originally suggested by Toivola *et al.* and Pekny and Lane.

Keywords

intermediate filament proteins, chaperones, stress response, phenotypes, mutation, background effects

Open Peer Review

Reviewer Status

	Invited Reviewers	
	1	2
version 1 published 30 Sep 2019		

F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

- Milos Pekny**, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
- Doug DeSimone**, University of Virginia, School of Medicine, Charlottesville, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Michael W. Klymkowsky (Michael.Klymkowsky@colorado.edu)

Author roles: Klymkowsky MW: Conceptualization, Formal Analysis, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Klymkowsky MW. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Klymkowsky MW. **Filaments and phenotypes: cellular roles and orphan effects associated with mutations in cytoplasmic intermediate filament proteins [version 1; peer review: 2 approved]** F1000Research 2019, 8(F1000 Faculty Rev):1703 (<https://doi.org/10.12688/f1000research.19950.1>)

First published: 30 Sep 2019, 8(F1000 Faculty Rev):1703 (<https://doi.org/10.12688/f1000research.19950.1>)

Introduction

Cytoplasmic intermediate filaments (IFs), together with actin-based microfilaments and tubulin-based microtubules, combine to form the eukaryotic cytoskeleton. (Here, I concentrate on cytoplasmic IFs and [almost] completely ignore the nuclear lamins as well as the septins associated with tight junctions.) Microtubules and microfilaments are unambiguously essential elements of eukaryotic cells. Notwithstanding claims that IFs are the “primary determinants of cell architecture and plasticity”¹ and play a “pivotal role in regulatory cell architecture and function”², the roles played by IFs are more enigmatic and context-specific than those of microtubules and microfilaments, specifically given the observation that for many (most) IF polypeptide (IFp)-encoding genes, mice homozygous for null mutations are viable and fertile (Table 1). The goal of this review is to draw attention to complications in the interpretation of the phenotypes associated with null and antimorphic (dominant negative) mutations in IFp-encoding genes, a point also made by Bouameur and Magin³.

The cytoplasmic IFp genes appear to have evolved from the nuclear lamins^{4,5}. In this light and given the viable phenotypes associated with many IFp-null mutations in the mouse (see below), it is interesting to note that cytoplasmic IFs have been lost in the arthropods, although they are present in other invertebrates^{6–8}. In collembolans, copepods, and tardigrades, the cytoplasmic IFs that are present appear to be formed by lamin-like proteins⁹. Lamins appear to be core components of eukaryotes⁵.

While analyzing the positive and negative effects of selection on specific genetic loci is complex, we can assume that if a functional version of a gene is necessary for an organism’s survival or reproductive success, loss of function (LoF) alleles will be rare or absent from a population. The Exome Aggregation Consortium (ExAC) database (<http://exac.broadinstitute.org>) contains a collection of exome sequences of 60,706 unrelated people, unaffected “by severe pediatric disease”. Allelic variants likely (although by no means certain) to produce a LoF effect, that is, stop codons and defects in splice junctions near the 5’ start of the gene, were identified. Lek *et al.*¹⁰ defined the probability of LoF alleles existing within this collection using the “probability of being loss-of-function intolerant” (pLI) metric. The process of generating the pLI metric is complex and described in detail in the associated supplement “Constraints” by Samocha *et al.*, a part of Lek *et al.*¹⁰. A gene’s pLI score is an estimate of whether or not LoF mutations in that gene, whether homozygous or heterozygous, are efficiently removed from the population by selection. At the extremes, a pLI score of zero indicates that the gene is likely to be non-essential in most situations whereas a score of one indicates that it is essential (that is, it results in lethality or reproductive failure). A gene would be predicted to be essential if the frequency of LoF alleles (under conditions commonly experienced in the population) was zero (or very low) compared with its predicted occurrence, based on the assumption that it appeared randomly and without significant selective implications.

Human population genome sequence data, such as the ExAC database¹¹, reveal essentially zero probability of being loss-of-function intolerant (pLI) scores for most IFp genes (Table 1). The notable exceptions are vimentin (*VIM*) and keratin 1 (*KRT1*), which have pLI scores of 0.96 and 0.97, respectively, similar to that for the nuclear lamins (0.95 to 1.0), scores indicative of an essential gene whose inactivation by mutation leads to strong negative selection. In this light, species differences between mouse and human may be relevant¹². Other IFp genes with non-zero pLI scores are the keratins *KRT18* (pLI: 0.62) and *KRT5* (pLI: 0.47) and the neural IFp α -internexin (*INA*) gene (pLI: 0.29). Nonetheless, it is unambiguously the case that mutations in IFp-encoding genes play a causal role in a number of human diseases^{13,14} (<http://www.interfil.org>). An example is a dominant-acting missense mutation in *VIM* that disrupts IF formation, leading to “pulverulent cataract in a 45-year-old individual”¹⁵.

My own introduction to IFs was through intracellular injection studies that revealed a lack of overt effects following the disruption of IF organization in the admittedly highly artificial context of cell culture¹⁶ (similar to results reported by 17,18). Subsequent studies reported effects on lipid synthesis and nuclear morphology in cultured cells that would normally express *VIM*^{19,20} but these phenotypes were not apparent in *VIM*^{-/-} mice²¹. Real progress was made when investigators moved from cultured cells to developing organisms. In *Xenopus*, KRT-type IFs were implicated in the mechanical process of gastrulation²², an observation supported and extended by a recent study by Sonavane *et al.*²³. Mutations in genes encoding KRT IFps resulted in the mechanical fragility of mouse and human epidermis (reviewed in 24,25). In muscle, the absence of the IF protein desmin (DES) or the expression of mutant DES led to structural defects in both skeletal and cardiac muscle^{26–28}. Since then, increasingly thorough analyses have established the mechanical roles of IFs in cells and tissues^{3,29–31}.

Unanswered questions

Which of the phenotypic effects associated with mutations in IFp-encoding genes are direct, that is, due to the absence of an intact IF network, and which are indirect, due to the redistribution of proteins normally associated with IFs, remains to be resolved. That IFps interact with cellular factors was indicated to us by the observation that *Xenopus* vimentin protein failed to assemble a filament network in *Xenopus* oocytes³². The role of host cell factors has been further illustrated by studies in which human IFps were expressed in *Drosophila*, which has no cytoplasmic IFs of its own. In *Drosophila* S2 cells and mesenchymal tissues (the types of tissues that would normally express *VIM* in humans), human vimentin was unable to form filament networks; on the other hand, it formed cage-like filament networks around the nuclei of internal epithelial cells⁸.

There are a number of tools available to visualize protein-protein interaction networks³³. (It is worth noting the formal distinction between a polypeptide gene product and a functional protein, which may be composed of multiple different gene products and multiple subunit polypeptides. See

Table 1. Null mutations in mice, BioGRID interacting polypeptides, and human pLI scores for intermediate filament subunit proteins.

Intermediate filament subunit protein	Number of interacting proteins BioGRID (unique)	Predicted versus expected loss of function (LoF)	Probability of LoF intolerance (pLI)	Mouse knockout
Vimentin (VIM)	315	2/14	0.96	Yes
Peripherin (PRPH)	28	16/15	0.0	Yes
Desmin (DES)	48	7/16.7	0.0	Yes
Synemin (SYNM)	22	21/26	0.0	Yes
Glial fibrillary acidic protein (GFAP)	103	9/13	0.0	Yes
NFL (NEFL)	68	Not reported	Not reported	Yes
NFM (NEFM)	52	5/14.5	0.04	Yes
NFH (NEFH)	26	7/14	0.0	Yes
Internexin (INA)	45	2/7.8	0.29	Yes
Syncoilin (SYNC)	50	4/10.6	0.04	Yes
Nestin (NES)	69	13/30	0.0	Yes
Nebulin (NEB)	27	79/249	0.0	Yes
Keratin 1 (Krt1)	96	2/19.7	0.97	Not found
Keratin 2 (Krt2)	84	5/16.3	0.07	Not found
Keratin 3 (Krt3)	24	10/12.3	0.0	Not found
Keratin 4 (Krt4)	26	9/21	0.0	Yes
Keratin 5 (Krt5)	86	3/14.2	0.47	Yes
Keratin 6 (Krt6)	None so far	9/13.8	0.0	Yes
Keratin 7 (Krt7)	22	12.6/13	0.0	Yes
Keratin 8 (Krt8)	80	10/14	0.0	Yes
Keratin 9 (Krt9)	72	7/14.5	0.0	Yes
Keratin 10 (Krt10)	86	6/17.3	0.02	Yes
Keratin 12 (Krt12)	4	16/16.3	0.0	Yes
Keratin 13 (Krt13)	72	6/10.9	0.0	Not found
Keratin 14 (Krt14)	65	4/11.9	0.07	Yes
Keratin 15 (Krt15)	148	16.2/20	0.0	Not found
Keratin 16 (Krt16)	57	13/12.3	0.0	Yes
Keratin 17 (Krt17)	182	10/14.5	0.0	Yes
Keratin 18 (Krt18)	126	2/12	0.62	Yes
Keratin 19 (Krt19)	72	6/13	0.0	Yes
Keratin 20 (Krt20)	30	10/14.1	0.0	Not found
LMNA	802	1/19	0.99	Yes
LMNB1	122	2/18	0.95	Yes
LMNB2	59	1/20	1.0	Yes

Null mutations in mice, BioGRID interacting polypeptides, and human pLI scores for intermediate filament subunit proteins included lamin A/C^{34,35}, B1 and B2 type lamins³⁶, vimentin³⁷, glial fibrillary acidic protein (GFAP)^{38,39}, desmin^{27,28,40,41}, nestin^{42,43}, the three neurofilament proteins (NEFL, NEFM, and NEFH)⁴⁴⁻⁵⁰, peripherin^{51,52}, internexin⁵³, synemin^{54,55}, syncoilin⁵⁶, Krt4⁵⁷, Krt5⁵⁸, Krt6⁵⁹, Krt7⁶⁰, Krt8⁶¹⁻⁶³, Krt9⁶⁴, Krt10⁶⁵, Krt12⁶⁶, Krt14⁶⁷⁻⁶⁹, Krt16⁷⁰, Krt17⁷¹, Krt18⁷², and K19^{73,74}. These studies have been extended in mice missing all type I and type II keratins^{75,76}. Interaction partner estimates are from <https://thebiogrid.org> (accessed July 4, 2019).

<https://bioliteracy.blog/2018/05/15/when-is-a-gene-product-a-protein-when-is-it-a-polypeptide>.) An often-used tool is STRING⁷⁷, which displays a range of interactions graphically. Here, I have used STRING to present a crude snapshot of interactions involving VIM and DES proteins (Figure 1). One immediately notes that a number of known DES-interacting proteins⁷⁸ derived from the BioGRID database⁷⁹ are absent (Table 1 and Figure 1). I refer to interacting proteins that may be influenced by the absence of an IFp as orphan proteins. In the absence of an intact IF network, such orphans may adopt wayward (toxic) structures and interact inappropriately with other cellular structures, leading to secondary phenotypes, an idea originally suggested by Toivola *et al.*⁸⁰ and Pekny and Lane⁸¹ (see also Capetanaki *et al.*⁸²). It is likely that many functionally significant interactions have yet to be identified. An example is the molecular chaperone α B-crystallin (CRYAB), whose STRING interaction network (Figure 1) does not include any IFps. In this case, the orphan effect involves defects in the assembly of IF networks in astrocytes associated with mutations in the gene encoding glial fibrillary acidic protein (GFAP). Such mutations lead to increased levels of soluble

oligomers that act to inhibit proteasome activity in Alexander disease⁸³. In mouse models of the disease, inhibition of CRYAB expression led to increased mortality whereas increased CRYAB expression “rescued animals from terminal seizures”^{83,84}. In a sense, the chaperone provides a home or safe haven for the non-filamentous GFAP oligomers, an idea suggested by the chaperone network described by Taipale *et al.*⁸⁵ and others (see below).

The gigaxonin (GAN) gene encodes a E3-ubiquitin adaptor protein involved in IF network organization and degradation^{86–88}. GAN is mutated in the fatal human disease giant axonal neuropathy. Our studies revealed the conditional nature of the GAN-associated VIM organization phenotype in two patient-derived primary fibroblast cell lines⁸⁹. Of note, the GAN protein does not appear in lists of IF associated proteins or in the STRING data base. In other cell types, the absence of glial IF networks was found to lead to an increase in neuronal and glial cell division and improvements in post-trauma regeneration^{90–92} as well as effects on gene




Figure 1. Interaction networks (derived from the STRING-DB website) for vimentin and desmin. We list the desmin-interacting proteins—from Costa *et al.*⁷⁸ (2004)—that are absent from either map. As an example, chaperone α B-crystallin (CRYAB) is absent. Its interaction map is displayed in the upper right hand corner.

expression in neighboring microglia⁹³. The mechanism(s) underlying these effects have yet to be resolved.

Traub *et al.* described the interaction between a number of IFPs and nucleic acids^{94–97}. (In our own lab, we routinely purified VIM on single-stranded DNA columns.) It is worth noting that the VIM^{-/-} mouse generated by Colucci-Guyon *et al.*³⁷ may leave the N-terminal DNA binding domain intact. Soluble (tetrameric) forms of IFPs have been identified⁹⁸ and found in the nuclei of cells⁹⁹. VIM has been reported to influence transforming growth factor beta (TGFβ)-Slug (Snai2)¹⁰⁰ and nuclear factor kappa B (NF-κB)¹⁰¹ signaling as well as the NLRP3 inflammasome¹⁰², all of which are known to influence gene expression. Similarly, desmin has been reported to enter the nucleus, associated with chromatin, and influence gene expression¹⁰³. These observations raise the obvious question, answerable by RNA-seq (RNA-sequencing) and proteomic studies, how does the expression (or absence) of a particular IFP influence the overall pattern of gene expression? This is a question that, to my knowledge, has not been directly answered, even though VIM-free human SW13 cells and the ability to control expression of various IFPs (including VIM) have been available for some time^{19,75,104–108}. Steps in this direction have been made, however. These include a microarray analysis of control and Alzheimer's disease model mice null for both *GFAP* and *VIM*; these authors reported that the expression of hundreds of genes was altered⁹³. A similar response has been found in DES^{-/-} mice^{109,110}. Levels of inflammation, interleukin 1 beta (IL-1β) expression, and endothelial and alveolar epithelial barrier permeability, together with tissue remodeling and fibrosis, are attenuated in the lungs of VIM^{-/-} mice¹⁰². The absence of KRT expression influenced epidermal barrier formation and mitochondrial lipid composition and activity in the cornified epithelia of transgenic mice¹¹¹. In some cases, IFP concentrations have been found to increase dramatically in the context of cell stress, suggesting that IFPs themselves may act as stress proteins, part of a stress response network¹¹².

There are multiple reports of interactions between IFs and mitochondria^{82,111,113–123}, as well as with endoplasmic reticulum, which interacts with mitochondria^{124,125}, and the microtubule-anchoring centrosome¹²⁶. The disruption of these interactions could lead to a range of effects, including mitochondrial dysfunction, which has been reported in a number of IFP-null mice. Given the central role of mitochondrial activity in a wide range of tissues and cellular processes^{127–130}, such effects may be more impactful than the “primary” defects arising from the absence of the IF network itself. As an example, mitochondrial effects have been linked to the behavior of primary cilia, an organelle closely involved in a number of intra- and intercellular signaling systems active during embryonic development and within mature tissues¹³¹. Abnormal mitochondrial structure, function, and activity may be involved in a wide range of IF-associated phenotypes, such as increased oxidative stress in macrophages, leading to vascular inflammation and attenuated atherosclerosis in mice¹³², the accumulation of body fat¹³³, and differences in the growth behavior of wild-type and VIM-null cells¹¹⁵.

Perhaps the most obvious example of IF–stress interactions and organismic phenotypes is the cardiomyopathy phenotypes observed in DES^{-/-} mice and associated with human DES mutations¹³⁴. DES^{-/-} mice display “progressive degeneration and necrosis of the myocardium” and defects in mitochondrial distribution, morphology, and function^{135,136}. Weisleder *et al.*¹³⁶ observed that the most severe aspects of the DES^{-/-} phenotype in mice were suppressed by the over-expression of Bcl2, a mitochondrial outer membrane protein involved in the regulation of apoptosis¹³⁷. In our own studies, expression of the related anti-apoptotic protein Bcl-xL suppressed neural crest defects associated with the loss of the transcription factor Slug (Snai2) through the activation of NF-κB signaling¹³⁸, suggesting the possible involvement of complex “downstream” effects. Diokmetzidou *et al.*¹³⁹ followed up on the rescue ability of the mouse DES^{-/-} phenotype by adopting a strategy first applied by the Goldman⁸³, Messing⁸⁴, and Quinlan^{140,141} groups, who found that the expression of the molecular chaperone CRYAB¹⁴² suppressed the toxicity of GFAP mutants in mouse models of Alexander disease (see above). In the case of DES^{-/-}-null mice, the Capetanaki group found that expression of αB-crystallin ameliorated many of the mitochondrial defects displayed in heart muscle, leading to “almost wild-type levels” of mitochondrial activity¹⁴³. In a related study, this group found that over-expression of tumor necrosis factor alpha (TNFα) led to expression of the simple epithelial keratins Krt8 and Krt18 in the heart; these keratins assumed many of the structural roles normally carried out by DES and rescued mitochondrial defects¹⁴⁴. In the absence of these keratins (and DES), critical desmosomal and adherens junction proteins, all known to influence intracellular signaling systems and gene expression networks, were displaced^{61,145–147}. These observations reinforce the idea that the loss of wild-type DES in particular, and IFPs in general, can lead to the mislocalization of proteins known to play important roles in the regulation of mitochondrial function and gene expression.

Simple epithelial keratins provide a classic example of both genetic background effects and the role of IFPs under conditions of cellular and tissue stress. The first reported knockout of any IFP was Krt8. In C57BL/6 mice, *Krt8*^{-/-} animals displayed about 94% embryonic lethality⁶². However, when crossed into the FVB/N genetic background, embryonic lethality was suppressed, although *Krt8*^{-/-} mice displayed colonic hyperplasia and inflammatory phenotypes in desmin null mice¹⁴⁸. In 20-week-old *Krt8*^{-/-} (FVB/N) mice, analysis of liver structure revealed no overt phenotypes associated with the absence of KRT filaments. KRT filaments do not form in this simple epithelial tissue in the absence of Krt8. On the other hand, a rapid increase in blood flow and the cellular stresses associated with partial hepatectomy led to 100% lethality in *Krt8*^{-/-} (FVB/N) mice compared with significant levels of survival in heterozygous and wild-type mice¹⁴⁹. A similar increase in hepatectomy-associated lethality was observed in *Krt18*^{-/-} mice¹⁵⁰ as well as in humans with KRT mutations/variants^{13,151}. Clearly, genetic background effects, the presence of particular stresses, and cellular responses to those stresses play important roles in the various disease phenotypes associated with IFP variants¹⁵².

There have been a number of reports on roles for VIM in cell migration and epithelial-mesenchymal transition (for example, 153–157), a key developmental event associated most dramatically with the formation and migration of neural crest cells and their roles in a number of tissues, particularly the vertebrate craniofacial skeleton^{156,158–160}. Yet to my knowledge, no craniofacial or cell migration-dependent defects have been described in *VIM*^{-/-} mice or *VIM* mutations/variants in humans. It remains unclear whether the phenotypes associated with aberrant *VIM* expression are due to the absence of *VIM per se* or to secondary effects involving orphaned VIM-associated proteins. An obvious experiment would be to ask whether increased expression of molecular chaperones, such as α B-crystallin, rescued any or all of such cell migratory phenotypes.

The size of the IFp gene family raises another recently identified potential complication in the link between mutation and phenotype. As reviewed by Wilkinson (161 and references therein), non-sense mutations can provoke a non-sense-mediated, RNA decay-based gene regulatory feedback system that can lead to the activation of (often) sequence-related genes. More generally, the viability of biological systems in the face of molecular level noise (including mutations) is enhanced by a range of adaptive molecular chaperones and feedback

networks^{85,162,163}. Given the effects of expressing chaperones on mutant IFp phenotypes (see above), a more complete understanding of the molecular mechanisms responsible for the phenotypes associated with mutant IFp genes is likely to suggest more effective therapeutic strategies, such as the use of small molecule “chemical chaperones”¹⁶⁴, as well as a deeper understanding of the responsive interaction networks that underlie biological behaviors.

Acknowledgments

Because of space (and my own) limitations, I beg forgiveness if I have failed to cite relevant papers. This review had its origins in an F1000 article commentary (<https://f1000.com/prime/734261963>). I thank Bishr Omary (University of Michigan) for helpful suggestions and Yassemi Capetanaki (Biomedical Research Foundation of the Academy of Athens), Milos Pekny (University of Gothenburg), John Eriksson (Åbo Akademi University), Robin Dowell (University of Colorado), and Pierre Coulombe (University of Michigan Medical School) for answering some of my questions. Of course, all errors and mis- and over-interpretations and speculations are entirely my own responsibility.

References



- Herrmann H, Strelkov SV, Burkhard P, et al.: **Intermediate filaments: primary determinants of cell architecture and plasticity.** *J Clin Invest.* 2009; **119**(7): 1772–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lowery J, Kuczumarski ER, Herrmann H, et al.: **Intermediate Filaments Play a Pivotal Role in Regulating Cell Architecture and Function.** *J Biol Chem.* 2015; **290**(28): 17145–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Bouameur JE, Magin TM: **Lessons from Animal Models of Cytoplasmic Intermediate Filament Proteins.** *Subcell Biochem.* 2017; **82**: 171–230.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Kollmar M: **Polyphyly of nuclear lamin genes indicates an early eukaryotic origin of the metazoan-type intermediate filament proteins.** *Sci Rep.* 2015; **5**: 10652.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Koreny L, Field MC: **Ancient Eukaryotic Origin and Evolutionary Plasticity of Nuclear Lamina.** *Genome Biol Evol.* 2016; **8**(9): 2663–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bartnik E, Weber K: **Widespread occurrence of intermediate filaments in invertebrates: Common principles and diversion.** *Eur J Cell Bio.* 1989; **50**(1): 17–33.
[Reference Source](#)
- Cho A, Kato M, Whitwam T, et al.: **An Atypical Tropomyosin in *Drosophila* with Intermediate Filament-like Properties.** *Cell Rep.* 2016; **16**(4): 928–938.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Gullmets J, Torvaldson E, Lindqvist J, et al.: **Internal epithelia in *Drosophila* display rudimentary competence to form cytoplasmic networks of transgenic human vimentin.** *FASEB J.* 2017; **31**(12): 5332–5341.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Hering L, Bouameur JE, Reichelt J, et al.: **Novel origin of lamin-derived cytoplasmic intermediate filaments in tardigrades.** *eLife.* 2016; **5**: e11117.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Lek M, Karczewski KJ, Minikel EV, et al.: **Analysis of protein-coding genetic variation in 60,706 humans.** *Nature.* 2016; **536**(7616): 285–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Karczewski KJ, Weisburd B, Thomas B, et al.: **The ExAC browser: displaying reference data information from over 60 000 exomes.** *Nucleic Acids Res.* 2017; **45**(D1): D840–D845.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Liao BY, Zhang J: **Null mutations in human and mouse orthologs frequently result in different phenotypes.** *Proc Natl Acad Sci U S A.* 2008; **105**(19): 6987–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Omary MB, Coulombe PA, McLean WI: **Intermediate filament proteins and their associated diseases.** *N Engl J Med.* 2004; **351**(20): 2087–100.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Szeverenyi I, Cassidy AJ, Chung CW, et al.: **The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases.** *Hum Mutat.* 2008; **29**(3): 351–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Müller M, Bhattacharya SS, Moore T, et al.: **Dominant cataract formation in association with a vimentin assembly disrupting mutation.** *Hum Mol Genet.* 2009; **18**(6): 1052–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Klymkowsky MW: **Intermediate filaments in 3T3 cells collapse after intracellular injection of a monoclonal anti-intermediate filament antibody.** *Nature.* 1981; **291**(5812): 249–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lin JJ, Feramisco JR: **Disruption of the *in vivo* distribution of the intermediate filaments in fibroblasts through the microinjection of a specific monoclonal antibody.** *Cell.* 1981; **24**(1): 185–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Klymkowsky MW, Miller RH, Lane EB: **Morphology, behavior, and interaction of cultured epithelial cells after the antibody-induced disruption of keratin filament organization.** *J Cell Biol.* 1983; **96**(2): 494–509.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sarria AJ, Panini SR, Evans RM: **A functional role for vimentin intermediate filaments in the metabolism of lipoprotein-derived cholesterol in human SW-13 cells.** *J Biol Chem.* 1992; **267**(27): 19455–63.
[PubMed Abstract](#)
- Sarria AJ, Lieber JG, Nordeen SK, et al.: **The presence or absence of a**

- vimentin-type intermediate filament network affects the shape of the nucleus in human SW-13 cells. *J Cell Sci.* 1994; **107**(Pt 6): 1593–607.
[PubMed Abstract](#)
21. Evans RM: **Vimentin: the conundrum of the intermediate filament gene family.** *Bioessays.* 1998; **20**(1): 79–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Klymkowsky MW, Shook DR, Maynell LA: **Evidence that the deep keratin filament systems of the *Xenopus* embryo act to ensure normal gastrulation.** *Proc Natl Acad Sci U S A.* 1992; **89**(18): 8736–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. **F** Sonavane PR, Wang C, Dzamba B, *et al.*: **Mechanical and signaling roles for keratin intermediate filaments in the assembly and morphogenesis of *Xenopus* mesoderm tissue at gastrulation.** *Development.* 2017; **144**(23): 4363–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
24. Klymkowsky MW: **Intermediate filaments. Getting under the skin.** *Nature.* 1991; **354**(6351): 264.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Fuchs E, Weber K: **Intermediate filaments: structure, dynamics, function, and disease.** *Annu Rev Biochem.* 1994; **63**: 345–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Cary RB, Klymkowsky MW: **Disruption of intermediate filament organization leads to structural defects at the intersomite junction in *Xenopus* myotomal muscle.** *Development.* 1995; **121**(4): 1041–52.
[PubMed Abstract](#)
27. Li Z, Colucci-Guyon E, Pinçon-Raymond M, *et al.*: **Cardiovascular lesions and skeletal myopathy in mice lacking desmin.** *Dev Biol.* 1996; **175**(2): 362–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Milner DJ, Weitzer G, Tran D, *et al.*: **Disruption of muscle architecture and myocardial degeneration in mice lacking desmin.** *J Cell Biol.* 1996; **134**(5): 1255–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Kreplak L, Fudge D: **Biomechanical properties of intermediate filaments: from tissues to single filaments and back.** *Bioessays.* 2007; **29**(1): 26–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Buehler MJ: **Mechanical players-The role of intermediate filaments in cell mechanics and organization.** *Biophys J.* 2013; **105**(8): 1733–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. **F** Guo M, Ehrlicher AJ, Mahammad S, *et al.*: **The role of vimentin intermediate filaments in cortical and cytoplasmic mechanics.** *Biophys J.* 2013; **105**(7): 1562–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
32. Dent JA, Cary RB, Bachant JB, *et al.*: **Host cell factors controlling vimentin organization in the *Xenopus* oocyte.** *J Cell Biol.* 1992; **119**(4): 855–866.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Agapito G, Guzzi PH, Cannataro M: **Visualization of protein interaction networks: problems and solutions.** *BMC Bioinformatics.* 2013; **14** Suppl 1: S1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Sullivan T, Escalante-Alcalde D, Bhatt H, *et al.*: **Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy.** *J Cell Biol.* 1999; **147**(5): 913–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Nikolova V, Leimena C, McMahon AC, *et al.*: **Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice.** *J Clin Invest.* 2004; **113**(3): 357–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. **F** Kim Y, Sharov AA, McDole K, *et al.*: **Mouse B-type lamins are required for proper organogenesis but not by embryonic stem cells.** *Science.* 2011; **334**(6063): 1706–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
37. Colucci-Guyon E, Portier MM, Dunia I, *et al.*: **Mice lacking vimentin develop and reproduce without an obvious phenotype.** *Cell.* 1994; **79**(4): 679–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Pekny M, Leveen P, Pekna M, *et al.*: **Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally.** *EMBO J.* 1995; **14**(8): 1590–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. McCall MA, Gregg RG, Behringer RR, *et al.*: **Targeted deletion in astrocyte intermediate filament (*Gfap*) alters neuronal physiology.** *Proc Natl Acad Sci U S A.* 1996; **93**(13): 6361–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Li Z, Mericskay M, Agbulut O, *et al.*: **Desmin Is Essential for the Tensile Strength and Integrity of Myofibrils but Not for Myogenic Commitment, Differentiation, and Fusion of Skeletal Muscle.** *J Cell Biol.* 1997; **139**(1): 129–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Thornell L-E, Carlsson L, Li Z, *et al.*: **Null mutation in the desmin gene gives rise to a cardiomyopathy.** *J Mol Cell Cardiol.* 1997; **29**(8): 2107–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Mohseni P, Sung H-K, Murphy AJ, *et al.*: **Nestin is not essential for development of the CNS but required for dispersion of acetylcholine receptor clusters at the area of neuromuscular junctions.** *J Neurosci.* 2011; **31**(32): 11547–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. **F** Lindqvist J, Torvaldson E, Gullmets J, *et al.*: **Nestin contributes to skeletal muscle homeostasis and regeneration.** *J Cell Sci.* 2017; **130**(17): 2833–2842.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
44. Elder GA, Friedrich VL Jr, Bosco P, *et al.*: **Absence of the mid-sized neurofilament subunit decreases axonal calibers, levels of light neurofilament (NF-L), and neurofilament content.** *J Cell Biol.* 1998; **141**(3): 727–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Rao MV, Houseweart MK, Williamson TL, *et al.*: **Neurofilament-dependent radial growth of motor axons and axonal organization of neurofilaments does not require the neurofilament heavy subunit (NF-H) or its phosphorylation.** *J Cell Biol.* 1998; **143**(1): 171–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Elder GA, Friedrich VL Jr, Pereira D, *et al.*: **Mice with disrupted mid-sized and heavy neurofilament genes lack axonal neurofilaments but have unaltered numbers of axonal microtubules.** *J Neurosci Res.* 1999; **57**(1): 23–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Križ J, Zhu Q, Julien JP, *et al.*: **Electrophysiological properties of axons in mice lacking neurofilament subunit genes: Disparity between conduction velocity and axon diameter in absence of NF-H.** *Brain Res.* 2000; **885**(1): 32–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Rao MV, Campbell J, Yuan A, *et al.*: **The neurofilament middle molecular mass subunit carboxyl-terminal tail domains is essential for the radial growth and cytoskeletal architecture of axons but not for regulating neurofilament transport rate.** *J Cell Biol.* 2003; **163**(5): 1021–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Dubois M, Strazielle C, Julien JP, *et al.*: **Mice with the deleted neurofilament of low molecular weight (Nefl) gene: 2. Effects on motor functions and spatial orientation.** *J Neurosci Res.* 2005; **80**(6): 751–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Dubois M, Lalonde R, Julien JP, *et al.*: **Mice with the deleted neurofilament of low-molecular-weight (Nefl) gene: 1. Effects on regional brain metabolism.** *J Neurosci Res.* 2005; **80**(6): 741–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Larivière RC, Nguyen MD, Ribeiro-da-Silva A, *et al.*: **Reduced number of unmyelinated sensory axons in peripherin null mice.** *J Neurochem.* 2002; **81**(3): 525–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Larivière RC, Beaulieu J-M, Nguyen MD, *et al.*: **Peripherin is not a contributing factor to motor neuron disease in a mouse model of amyotrophic lateral sclerosis caused by mutant superoxide dismutase.** *Neurobiol Dis.* 2003; **13**(2): 158–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Levavasseur F, Zhu Q, Julien JP: **No requirement of alpha-internexin for nervous system development and for radial growth of axons.** *Brain Res Mol Brain Res.* 1999; **69**(1): 104–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Garcia-Pelagio KP, Muriel J, O'Neill A, *et al.*: **Myopathic changes in murine skeletal muscle lacking synemin.** *Am J Physiol Cell Physiol.* 2015; **308**(6): C448–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Moorer MC, Buo AM, Garcia-Pelagio KP, *et al.*: **Deficiency of the intermediate filament synemin reduces bone mass in vivo.** *Am J Physiol Cell Physiol.* 2016; **311**(6): C839–C845.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. McCullagh KJA, Edwards B, Kemp MW, *et al.*: **Analysis of skeletal muscle function in the C57BL6/SV129 syncoilin knockout mouse.** *Mamm Genome.* 2008; **19**(5): 339–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Ness SL, Edelman W, Jenkins TD, *et al.*: **Mouse keratin 4 is necessary for internal epithelial integrity.** *J Biol Chem.* 1998; **273**(37): 23904–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Peters B, Kirfel J, Büssow H, *et al.*: **Complete Cytolysis and Neonatal Lethality in Keratin 5 Knockout Mice Reveal Its Fundamental Role in Skin Integrity and in Epidermolysis Bullosa Simplex.** *Mol Biol Cell.* 2001; **12**(6): 1775–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Wong P, Coulombe PA: **Loss of keratin 6 (K6) proteins reveals a function for intermediate filaments during wound repair.** *J Cell Biol.* 2003; **163**(2): 327–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Sandilands A, Smith FJ, Lunny DP, *et al.*: **Generation and Characterisation of Keratin 7 (K7) Knockout Mice.** *PLoS One.* 2013; **8**(5): e64404.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Johnson JL, Najor NA, Green KJ: **Desmosomes: Regulators of cellular signaling and adhesion in epidermal health and disease.** *Cold Spring Harb Perspect Med.* 2014; **4**(11): a015297.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Baribault H, Price J, Miyai K, *et al.*: **Mid-gestational lethality in mice lacking keratin 8.** *Genes Dev.* 1993; **7**(7A): 1191–202.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Baribault H: **Polarized and functional epithelia can form after the targeted inactivation of both mouse keratin 8 alleles.** *J Cell Biol.* 1991; **115**(6): 1675–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Fu DJ, Thomson C, Lunny DP, *et al.*: **Keratin 9 is Required for the structural integrity and terminal differentiation of the palmo/plantar epidermis.** *J Invest Dermatol.* 2014; **134**(3): 754–763.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Reichelt J, Büssow H, Grund C, *et al.*: **Formation of a normal epidermis**

- supported by increased stability of keratins 5 and 14 in keratin 10 null mice. *Mol Biol Cell*. 2001; **12**(6): 1557–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Kao WW, Liu CY, Converse RL, et al.: Keratin 12-deficient mice have fragile corneal epithelia. *Invest Ophthalmol Vis Sci*. 1996; **37**(13): 2572–84.
[PubMed Abstract](#)
67. Rugg EL, McLean WH, Lane EB, et al.: A functional “knockout” of human keratin 14. *Genes Dev*. 1994; **8**(21): 2563–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Lloyd C, Yu QC, Cheng J, et al.: The basal keratin network of stratified squamous epithelia: Defining K15 function in the absence of K14. *J Cell Biol*. 1995; **129**(5): 1329–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Paladini RD, Coulombe PA: Directed expression of keratin 16 to the progenitor basal cells of transgenic mouse skin delays skin maturation. *J Cell Biol*. 1998; **142**(4): 1035–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. Lessard JC, Coulombe PA: Keratin 16-null mice develop palmoplantar keratoderma, a hallmark feature of pachonychia congenita and related disorders. *J Invest Dermatol*. 2012; **132**(5): 1384–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. McGowan KM, Tong X, Colucci-Guyon E, et al.: Keratin 17 null mice exhibit age- and strain-dependent alopecia. *Genes Dev*. 2002; **16**(11): 1412–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
72. Magin TM, Schröder R, Leitgeb S, et al.: Lessons from keratin 18 knockout mice: formation of novel keratin filaments, secondary loss of keratin 7 and accumulation of liver-specific keratin 8-positive aggregates. *J Cell Biol*. 1998; **140**(6): 1441–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
73. Tamai Y, Ishikawa T, Bösl MR, et al.: Cytokeratins 8 and 19 in the mouse placental development. *J Cell Biol*. 2000; **151**(3): 563–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Stone MR, O'Neill A, Lovering RM, et al.: Absence of keratin 19 in mice causes skeletal myopathy with mitochondrial and sarcolemmal reorganization. *J Cell Sci*. 2007; **120**(Pt 22): 3999–4008.
[PubMed Abstract](#) | [Publisher Full Text](#)
75. Bellin RM, Sernett SW, Becker B, et al.: Molecular characteristics and interactions of the intermediate filament protein synemin. Interactions with alpha-actinin may anchor synemin-containing heterofilaments. *J Biol Chem*. 1999; **274**(41): 29493–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Bär J, Kumar V, Roth W, et al.: Skin fragility and impaired desmosomal adhesion in mice lacking all keratins. *J Invest Dermatol*. 2014; **134**(4): 1012–1022.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. von Mering C, Huynen M, Jaeggi D, et al.: STRING: a database of predicted functional associations between proteins. *Nucleic Acids Res*. 2003; **31**(1): 258–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Costa ML, Escalera R, Cataldo A, et al.: Desmin: molecular interactions and putative functions of the muscle intermediate filament protein. *Braz J Med Biol Res*. 2004; **37**(12): 1819–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Stark C, Breitkreutz BJ, Reguly T, et al.: BioGRID: a general repository for interaction datasets. *Nucleic Acids Res*. 2006; **34**(Database issue): D535–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
80. Toivola DM, Tao GZ, Habtezion A, et al.: Cellular integrity plus: organelle-related and protein-targeting functions of intermediate filaments. *Trends Cell Biol*. 2005; **15**(11): 608–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. Pekny M, Lane EB: Intermediate filaments and stress. *Exp Cell Res*. 2007; **313**(10): 2244–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Capetanaki Y, Papatheanasiou S, Diokmetzidou A, et al.: Desmin related disease: a matter of cell survival failure. *Curr Opin Cell Biol*. 2015; **32**: 113–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. Tang G, Perng MD, Wilk S, et al.: Oligomers of mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein alphaB-crystallin reverses the inhibition. *J Biol Chem*. 2010; **285**(14): 10527–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Hagemann TL, Boelens WC, Wawrousek EF, et al.: Suppression of GFAP toxicity by alphaB-crystallin in mouse models of Alexander disease. *Hum Mol Genet*. 2009; **18**(7): 1190–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
85. Taipale M, Tucker G, Peng J, et al.: A quantitative chaperone interaction network reveals the architecture of cellular protein homeostasis pathways. *Cell*. 2014; **158**(2): 434–448.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
86. Cleveland DW, Yamanaka K, Bomont P: Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway. *Hum Mol Genet*. 2009; **18**(8): 1384–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. Mohammad S, Murthy SN, Didonna A, et al.: Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation. *J Clin Invest*. 2013; **123**(5): 1964–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Bomont P: Degradation of the Intermediate Filament Family by Gigaxonin. In: *Intermediate Filament Associated Proteins. Methods Enzymol*. Elsevier; 2016; **569**: 215–231.
[PubMed Abstract](#) | [Publisher Full Text](#)
89. Klymkowsky MW, Plummer DJ: Giant axonal neuropathy: a conditional mutation affecting cytoskeletal organization. *J Cell Biol*. 1985; **100**(1): 245–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. Larsson A, Wilhelmsson U, Pekna M, et al.: Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP^{+/Vim⁻} mice. *Neurochem Res*. 2004; **29**(11): 2069–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
91. Wilhelmsson U, Li L, Pekna M, et al.: Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. *J Neurosci*. 2004; **24**(21): 5016–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
92. Widstrand A, Fajerson J, Wilhelmsson U, et al.: Increased neurogenesis and astrogenesis from neural progenitor cells grafted in the hippocampus of GFAP^{+/Vim⁻} mice. *Stem Cells*. 2007; **25**(10): 2619–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Kamphuis W, Kooijman L, Orre M, et al.: GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer's disease. *Glia*. 2015; **63**(6): 1036–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
94. Traub P, Nelson WJ, Kühn S, et al.: The interaction *in vitro* of the intermediate filament protein vimentin with naturally occurring RNAs and DNAs. *J Biol Chem*. 1983; **258**(3): 1456–66.
[PubMed Abstract](#)
95. Vorgias CE, Traub P: Nucleic acid-binding activities of the intermediate filament subunit proteins desmin and glial fibrillary acidic protein. *Z Naturforsch C*. 1986; **41**(9–10): 897–909.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. Traub P, Shoeman RL: Intermediate filament and related proteins: potential activators of nucleosomes during transcription initiation and elongation? *BioEssays*. 1994; **16**(5): 349–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Shoeman RL, Hüttermann C, Hartig R, et al.: Amino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cells. *Mol Biol Cell*. 2001; **12**(1): 143–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Soellner P, Quinlan RA, Franke WW: Identification of a distinct soluble subunit of an intermediate filament protein: tetrameric vimentin from living cells. *Proc Natl Acad Sci U S A*. 1985; **82**(23): 7929–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. Hobbs RP, Jacob JT, Coulombe PA: Keratins Are Going Nuclear. *Dev Cell*. 2016; **38**(3): 227–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
100. Cheng F, Shen Y, Mohanasundaram P, et al.: Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound healing via TGF- β -Slug signaling. *Proc Natl Acad Sci USA*. 2016; **113**(30): E4320–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
101. Huang SH, Chi F, Peng L, et al.: Vimentin, a Novel NF- κ B Regulator, Is Required for Meningitic *Escherichia coli* K1-Induced Pathogen Invasion and PMN Transmigration across the Blood-Brain Barrier. *PLoS One*. 2016; **11**(9): e0162641.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
102. dos Santos G, Rogel MR, Baker MA, et al.: Vimentin regulates activation of the NLRP3 inflammasome. *Nat Commun*. 2015; **6**: 6574.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
103. Fuchs CS, Gawlas P, Heher S, et al.: Desmin enters the nucleus of cardiac stem cells and modulates Nkx2.5 expression by participating in transcription factor complexes that interact with the *nkx2.5* gene. *Biol Open*. 2016; **5**(2): 140–153.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Sarria AJ, Nordeen SK, Evans RM: Regulated expression of vimentin cDNA in cells in the presence and absence of a preexisting vimentin filament network. *J Cell Biol*. 1990; **111**(2): 553–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
105. Lee MK, Xu Z, Wong PC, et al.: Neurofilaments are obligate heteropolymers *in vivo*. *J Cell Biol*. 1993; **122**(6): 1337–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
106. Cui C, Stambrook PJ, Parysek LM: Peripherin assembles into homopolymers in SW13 cells. *J Cell Sci*. 1995; **108**(Pt 10): 3279–84.
[PubMed Abstract](#)
107. Ho CL, Chin SS, Carnevale K, et al.: Translation initiation and assembly of peripherin in cultured cells. *Eur J Cell Biol*. 1995; **68**(2): 103–12.
[PubMed Abstract](#)
108. Holwell TA, Schweitzer SC, Evans RM: Tetracycline regulated expression of vimentin in fibroblasts derived from vimentin null mice. *J Cell Sci*. 1997; **110**(Pt 16): 1947–56.
[PubMed Abstract](#)

109. Fountoulakis M, Soumaka E, Rapti K, *et al.*: **Alterations in the heart mitochondrial proteome in a desmin null heart failure model.** *J Mol Cell Cardiol.* 2005; **38**(3): 461–474.
[PubMed Abstract](#) | [Publisher Full Text](#)
110. Psarras S, Mavroidis M, Sanoudou D, *et al.*: **Regulation of adverse remodelling by osteopontin in a genetic heart failure model.** *Eur Heart J.* 2012; **33**(15): 1954–1963.
[PubMed Abstract](#) | [Publisher Full Text](#)
111. Kumar V, Bouameur JE, Bär J, *et al.*: **A keratin scaffold regulates epidermal barrier formation, mitochondrial lipid composition, and activity.** *J Cell Biol.* 2015; **211**(5): 1057–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
112. Toivola DM, Strnad P, Habtezion A, *et al.*: **Intermediate filaments take the heat as stress proteins.** *Trends Cell Biol.* 2010; **20**(2): 79–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
113. Takahashi K, Folmer J, Coulombe PA: **Increased expression of keratin 16 causes anomalies in cytoarchitecture and keratinization in transgenic mouse skin.** *J Cell Biol.* 1994; **127**(2): 505–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Bannikova S, Zorov DB, Shoeman RL, *et al.*: **Stability and association with the cytomatrix of mitochondrial DNA in spontaneously immortalized mouse embryo fibroblasts containing or lacking the intermediate filament protein vimentin.** *DNA Cell Biol.* 2005; **24**(11): 710–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
115. Tolstonog GV, Belichenko-Weitzmann IV, Lu JP, *et al.*: **Spontaneously immortalized mouse embryo fibroblasts: growth behavior of wild-type and vimentin-deficient cells in relation to mitochondrial structure and activity.** *DNA Cell Biol.* 2005; **24**(11): 680–709.
[PubMed Abstract](#) | [Publisher Full Text](#)
116. Duan S, Yao Z, Zhu Y, *et al.*: **The Pirh2-keratin 8/18 interaction modulates the cellular distribution of mitochondria and UV-induced apoptosis.** *Cell Death Differ.* 2009; **16**(6): 826–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
117. **F** Tao GZ, Looi KS, Toivola DM, *et al.*: **Keratins modulate the shape and function of hepatocyte mitochondria: a mechanism for protection from apoptosis.** *J Cell Sci.* 2009; **122**(Pt 21): 3851–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
118. Tradewell ML, Durham HD, Mushynski WE, *et al.*: **Mitochondrial and axonal abnormalities precede disruption of the neurofilament network in a model of charcot-marie-tooth disease type 2E and are prevented by heat shock proteins in a mutant-specific fashion.** *J Neuropathol Exp Neurol.* 2009; **68**(6): 642–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
119. Nekrasova OE, Mendez MG, Chernovnenko IS, *et al.*: **Vimentin intermediate filaments modulate the motility of mitochondria.** *Mol Biol Cell.* 2011; **22**(13): 2282–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
120. Alvarado DM, Coulombe PA: **Directed expression of a chimeric type II keratin partially rescues keratin 5-null mice.** *J Biol Chem.* 2014; **289**(28): 19435–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
121. Chernovnenko IS, Matveeva EA, Gelfand VI, *et al.*: **Mitochondrial membrane potential is regulated by vimentin intermediate filaments.** *FASEB J.* 2015; **29**(3): 820–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
122. Helenius TO, Misiorek JO, Nyström JH, *et al.*: **Keratin 8 absence down-regulates colonocyte HMGCS2 and modulates colonic ketogenesis and energy metabolism.** *Mol Biol Cell.* 2015; **26**(12): 2298–310.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
123. **F** Silvander JSG, Kvarnström SM, Kumari-Ilieva A, *et al.*: **Keratins regulate β -cell mitochondrial morphology, motility, and homeostasis.** *FASEB J.* 2017; **31**(10): 4578–4587.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
124. Nishizawa M, Izawa I, Inoko A, *et al.*: **Identification of trichoplein, a novel keratin filament-binding protein.** *J Cell Sci.* 2005; **118**(Pt 5): 1081–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
125. Cerqua C, Anesti V, Pyakurel A, *et al.*: **Trichoplein/mitostatin regulates endoplasmic reticulum-mitochondria juxtaposition.** *EMBO Rep.* 2010; **11**(11): 854–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
126. Ibi M, Zou P, Inoko A, *et al.*: **Trichoplein controls microtubule anchoring at the centrosome by binding to Odf2 and ninein.** *J Cell Sci.* 2011; **124**(Pt 6): 857–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
127. Butow RA, Avadhani NG: **Mitochondrial signaling: the retrograde response.** *Mol Cell.* 2004; **14**(1): 1–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
128. Klymkowsky MW: **Mitochondrial activity, embryogenesis, and the dialogue between the big and little brains of the cell.** *Mitochondrion.* 2011; **11**(5): 814–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
129. Chae S, Ahn BY, Byun K, *et al.*: **A systems approach for decoding mitochondrial retrograde signaling pathways.** *Sci Signal.* 2013; **6**(264): rs4.
[PubMed Abstract](#) | [Publisher Full Text](#)
130. **F** Gammage PA, Frezza C: **Mitochondrial DNA: the overlooked oncogenome?** *BMC Biol.* 2019; **17**(1): 53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
131. **F** Chaudhry B, Henderson DJ: **Cilia, mitochondria, and cardiac development.** *J Clin Invest.* 2019; **129**(7): 2666–2668.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
132. **F** Häversen L, Sundelin JP, Mardinoglu A, *et al.*: **Vimentin deficiency in macrophages induces increased oxidative stress and vascular inflammation but attenuates atherosclerosis in mice.** *Sci Rep.* 2018; **8**(1): 16973.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
133. **F** Wilhelmsson U, Stillemark-Billton P, Borén J, *et al.*: **Vimentin is required for normal accumulation of body fat.** *Biol Chem.* 2019; **400**(9): 1157–1162.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
134. Hnia K, Ramsbacher C, Vermot J, *et al.*: **Desmin in muscle and associated diseases: beyond the structural function.** *Cell Tissue Res.* 2015; **360**(3): 591–608.
[PubMed Abstract](#) | [Publisher Full Text](#)
135. Milner DJ, Mavroidis M, Weisleder N, *et al.*: **Desmin cytoskeleton linked to muscle mitochondrial distribution and respiratory function.** *J Cell Biol.* 2000; **150**(6): 1283–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
136. Weisleder N, Taffet GE, Capetanaki Y: **Bcl-2 overexpression corrects mitochondrial defects and ameliorates inherited desmin null cardiomyopathy.** *Proc Natl Acad Sci U S A.* 2004; **101**(3): 769–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
137. **F** Popgeorgiev N, Jabbour L, Gillet G: **Subcellular Localization and Dynamics of the Bcl-2 Family of Proteins.** *Front Cell Dev Biol.* 2018; **6**: 13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
138. Zhang C, Carl TF, Trudeau ED, *et al.*: **An NF- κ B and slug regulatory loop active in early vertebrate mesoderm.** *PLoS One.* 2006; **1**(1): e106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
139. Diokmetzidou A, Soumaka E, Kloukina I, *et al.*: **Desmin and α B-crystallin interplay in the maintenance of mitochondrial homeostasis and cardiomyocyte survival.** *J Cell Sci.* 2016; **129**(20): 3705–3720.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
140. Nicholl ID, Quinlan RA: **Chaperone activity of alpha-crystallins modulates intermediate filament assembly.** *EMBO J.* 1994; **13**(4): 945–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
141. Peng MD, Wen SF, Gibbon T, *et al.*: **Glial fibrillary acidic protein filaments can tolerate the incorporation of assembly-compromised GFAP-delta, but with consequences for filament organization and alphaB-crystallin association.** *Mol Biol Cell.* 2008; **19**(10): 4521–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
142. Boelens WC: **Cell biological roles of α B-crystallin.** *Prog Biophys Mol Biol.* 2014; **115**(1): 3–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
143. **F** Galata Z, Kloukina I, Kostavasili I, *et al.*: **Amelioration of desmin network defects by α B-crystallin overexpression confers cardioprotection in a mouse model of dilated cardiomyopathy caused by LMNA gene mutation.** *J Mol Cell Cardiol.* 2018; **125**: 73–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
144. Papanthanasios S, Rickelt S, Soriano ME, *et al.*: **Tumor necrosis factor- α confers cardioprotection through ectopic expression of keratins K8 and K18.** *Nat Med.* 2015; **21**(9): 1076–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
145. Klymkowsky MW, Parr B: **The body language of cells: The intimate connection between cell adhesion and behavior.** *Cell.* 1995; **83**(1): 5–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
146. **F** Garcia-Gras E, Lombardi R, Giocondo MJ, *et al.*: **Suppression of canonical Wnt/ β -catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy.** *J Clin Invest.* 2006; **116**(7): 2012–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
147. Yang L, Chen Y, Cui T, *et al.*: **Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/ β -catenin signaling pathway in human lung cancer.** *Carcinogenesis.* 2012; **33**(10): 1863–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
148. Baribault H, Penner J, Iozzo RV, *et al.*: **Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice.** *Genes Dev.* 1994; **8**(24): 2964–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
149. Loranger A, Duclos S, Grenier A, *et al.*: **Simple epithelium keratins are required for maintenance of hepatocyte integrity.** *Am J Pathol.* 1997; **151**(6): 1673–83.
[PubMed Abstract](#) | [Free Full Text](#)
150. Ku NO, Michie S, Oshima RG, *et al.*: **Chronic hepatitis, hepatocyte fragility, and increased soluble phosphoglycokeratins in transgenic mice expressing a keratin 18 conserved arginine mutant.** *J Cell Biol.* 1995; **131**(5): 1303–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
151. Usachov V, Urban TJ, Fontana RJ, *et al.*: **Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury.** *BMC Med.* 2015; **13**: 196.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
152. **F** Omary MB: **Intermediate filament proteins of digestive organs: physiology**

- and pathophysiology. *Am J Physiol Gastrointest Liver Physiol.* 2017; **312**(6): G628–G634.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
153. Gilles C, Polette M, Zahm JM, *et al.*: **Vimentin contributes to human mammary epithelial cell migration.** *J Cell Sci.* 1999; **112**(Pt 24): 4615–25.
[PubMed Abstract](#)
154. Ivaska J, Pallari HM, Nevo J, *et al.*: **Novel functions of vimentin in cell adhesion, migration, and signaling.** *Exp Cell Res.* 2007; **313**(10): 2050–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
155. Ivaska J: **Vimentin: Central hub in EMT induction?** *Small GTPases.* 2011; **2**(1): 51–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
156. Vuoriluoto K, Haugen H, Kiviluoto S, *et al.*: **Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.** *Oncogene.* 2011; **30**(12): 1436–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
157. **F** Peuhu E, Virtakoivu R, Mai A, *et al.*: **Epithelial vimentin plays a functional role in mammary gland development.** *Development.* 2017; **144**(22): 4103–4113.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
158. Mendez MG, Kojima S, Goldman RD: **Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition.** *FASEB J.* 2010; **24**(6): 1838–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
159. **F** Battaglia RA, Delic S, Herrmann H, *et al.*: **Vimentin on the move: new developments in cell migration [version 1; peer review: 2 approved].** *F1000Res.* 2018; **7**. pii: F1000 Faculty Rev-1796.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
160. **F** Majumdar R, Steen K, Coulombe PA, *et al.*: **Non-canonical processes that shape the cell migration landscape.** *Curr Opin Cell Biol.* 2019; **57**: 123–134.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
161. **F** Wilkinson MF: **Genetic paradox explained by nonsense.** *Nature.* 2019; **568**(7751): 179–180.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
162. Rutherford SL: **Between genotype and phenotype: protein chaperones and evolvability.** *Nat Rev Genet.* 2003; **4**(4): 263–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
163. Lehtinen S, Bähler J, Orengo C: **Co-Expression Network Models Suggest that Stress Increases Tolerance to Mutations.** *Sci Rep.* 2015; **5**: 16726.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
164. Cortez L, Sim V: **The therapeutic potential of chemical chaperones in protein folding diseases.** *Prion.* 2014; **8**(2): pii: 28938.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:  

Editorial Note on the Review Process

F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1 **Doug DeSimone**

Department of Cell Biology, University of Virginia, School of Medicine, Charlottesville, VA, USA

Competing Interests: No competing interests were disclosed.

2 **Milos Pekny**

Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research